Retail / Pharmacy & Health Services · Deep dive

CVS Health Corporation

The $126B integrated pharmacy-PBM-insurer that raised 2026 guidance under new CEO David Joyner even as Caremark ceded PBM share to Express Scripts, Aetna took a Medicare Advantage star-ratings body blow, 900 stores went dark, activist Glenview took four board seats, and Amazon Pharmacy plus Mark Cuban's Cost Plus Drugs kept eating the edges.

at risk

Vertical integration is real but under attack on every leg — Caremark is shedding PBM share to Express Scripts and pass-through rivals, Aetna's star-ratings and prior-auth issues drive $1B+ swings and DOJ scrutiny, front-of-store retail is in structural decline with 1,170 stores gone by end of 2025, and Amazon Pharmacy plus Cost Plus Drugs are rewriting dispensing economics from below.

My take ★★ Very interesting ★ Interesting − Maybe ✗ Not interesting

Snapshot

CVS Health is the Fortune 6, ~$402B (FY2025) integrated pharmacy-PBM-insurer built from the 1963 Consumer Value Store, the 2007 Caremark merger, and the 2018 Aetna acquisition. Three segments — Health Services ($190.4B), Health Care Benefits ($143.4B) and Pharmacy & Consumer Wellness ($139.4B) — touch roughly one-third of every US retail prescription. David Joyner, a 35-year Caremark lifer promoted to CEO on October 18, 2024 after the board removed Karen Lynch, is running a credible turnaround that lifted 2026 adjusted EPS guidance to $7.90-$8.10 and pushed the market cap back above $126B — even as Caremark cedes PBM share, Aetna absorbs star-ratings damage, and Amazon Pharmacy plus Cost Plus Drugs eat the dispensing edges.

Founding story

CVS started on May 8, 1963 in Lowell, Massachusetts as the Consumer Value Store — a single discount health-and-beauty outlet opened by brothers Stanley and Sidney Goldstein with Ralph Hoagland. Pharmacies were added inside stores from 1967. In 1969 the Goldsteins sold the chain to Melville Corporation for stock; Melville broke itself up in 1996 and spun CVS out on NYSE with 1,400 stores. Everything since has been M&A: Revco (1997), Arbor (1998), Eckerd (2004), Caremark Rx (2007), Longs (2008), Target pharmacy (2015), Aetna (2018), Signify + Oak Street (2023). Larry Merlo (2011-2021) delivered Aetna and the 2014 tobacco exit ($2B walked-away sales). Karen Lynch (Feb 2021 - Oct 2024) delivered Signify and Oak Street but broke on the 2023 Aetna star-ratings downgrade and 2024 MLR blowout.

How it works

CVS is three interlocked machines. Retail pharmacy dispenses ~1.5B prescriptions a year through ~9,000 stores (down from ~9,900), plus front-of-store and MinuteClinic. Caremark PBM contracts with employers, plans and unions to negotiate rebates, adjudicate claims across a national network, and run mail-order, specialty and patient-support — booking on drug price and pocketing rebate spread plus admin fees. Aetna covers ~27M medical members across commercial, MA, Medicaid and dental — collecting premiums against MLR targets that swing operating income by the billion. Signify sends nurse practitioners into homes for MA risk-adjustment; Oak Street runs ~200 value-based primary-care clinics on capitated MA. Theory: machines feed each other; in practice each competes separately.

Product and business overview

Health Services ($190.4B FY2025) is Caremark plus Signify, Oak Street, MinuteClinic and specialty pharmacy — the biggest, fastest-growing segment. Health Care Benefits ($143.4B) is Aetna across commercial insured and self-insured, MA and Part D, Medicaid, dental and behavioral. Pharmacy & Consumer Wellness ($139.4B) is the retail store network, front-of-store and fulfilment infrastructure supporting Caremark specialty and mail. Consolidated revenue $402.1B FY2025 after eliminations.

Business model and pricing

Retail books per-prescription at PBM-negotiated reimbursement minus acquisition cost — a spread compressed under generic penetration and DIR-fee clawbacks, partially unwound by CMS’s 2024 rule. Front-of-store is straight product margin. Caremark books per-claim admin fees, rebate retention, spread pricing (plan-pay minus pharmacy-pay) and manufacturer-services fees — the exact economics the FTC challenged September 2024 and that Caremark agreed to modify in July 2026. Aetna books member-month premiums under CMS-capped MLR (85% large, 80% individual/small). Oak Street books capitated PMPM; Signify books per-visit. Consolidated adjusted operating margin ~4% FY2025.

Traction over time

Sources: CVS 10-Ks, Stock Analysis, MacroTrends, CVS Q2 2026 release, Drug Store News August 2026.

Market analysis

Three overlapping TAMs. US retail pharmacy dispenses ~$580B annually (IQVIA-cited), growing mid-single digits with volume in GLP-1s and specialty — both of which compress retail margins. US PBM services ran ~6.9B claims in 2025 with the big three at 80% share: Express Scripts 31%, Caremark 26%, Optum Rx 23% (Drug Channels, March 2026); pass-through PBMs gaining from a small base with FTC-forced practice changes now binding. US Medicare Advantage covers 32M+ members and is tightening: 2024 risk-adjustment methodology cut plan revenue, star-ratings audits are more punitive (Aetna’s National PPO 4.5→3.5 cost up to $1B in 2024), DOJ partially intervened in a broker-kickback case naming Aetna May 2025, and the Senate PSI’s October 2024 report sharpened political heat on prior-auth denials.

Competitive intel

UnitedHealth Group is the other integrated payer-PBM-provider — Optum Rx 23%, UnitedHealthcare #1 MA, OptumHealth ~90,000 providers — larger and better rated. Cigna Evernorth / Express Scripts took Caremark share 2024-2025. Walgreens Boots Alliance, taken private by Sycamore in 2025 ($10B equity, up to $23.7B EV), is a weaker ~8,000-store retail competitor now free of quarterly pressure. Amazon Pharmacy is 0.3% of dispensing but grew 50% YoY Q2 2025, hit ~4,500 same-day cities, and launched LA One Medical kiosks October 2025. Cost Plus Drugs publishes manufacturer cost + 15% + $3. Walmart, Kroger, Costco compete on price at grocery pharmacies. Pass-through PBMs (Navitus, Capital Rx, Prime, SmithRx, Rightway) pick off self-insured RFPs. Humana runs CenterWell as the Oak Street/Signify analogue. GoodRx leaks cash-pay margin.

History and evolution

• May 8, 1963 — Consumer Value Store #1 opens in Lowell MA.
• 1969 — Melville acquires CVS for stock; 17 stores.
• Nov 1996 — Melville breaks up; CVS Corporation lists on NYSE with ~1,400 stores.
• 1997-2008 — Revco ($2.8B), Arbor ($1.5B), Eckerd ($2.15B), Caremark ($26.5B), Longs ($2.9B).
• March 2011 — Larry Merlo CEO. Feb 2014 — Exits tobacco (~$2B walked-away sales).
• Dec 2015 — Target pharmacy $1.9B. Nov 28, 2018 — Closes $69B Aetna after DOJ approval.
• Feb 2021 — Karen Lynch succeeds Merlo. Mar/May 2023 — Signify $8B / Oak Street $10.6B close.
• August 2023 — Blue Shield of California drops Caremark for Amazon + Cost Plus + Prime + Abarca (~$500M annual savings).
• Oct 2023 — 900-store closure plan; Aetna National PPO stars 4.5→3.5.
• Feb 2024 — Cowhey CFO. Sep 2024 — FTC files action vs. Caremark/Express Scripts/Optum Rx on insulin rebates.
• Oct 18, 2024 — Board removes Lynch; Joyner CEO. Nov 18, 2024 — Glenview four board seats.
• 2025 — 270 more closures; Ohio Board of Pharmacy $1.5M settlement (27 safety cases); DOJ partially intervenes in MA broker-kickback case naming Aetna (May).
• July 2026 — CVS settles FTC Caremark case; binding rebate, network and vertical-integration changes.
• Aug 5, 2026 — Q2 2026 $106.1B (+7.3%); FY EPS guide $7.90-$8.10; mkt cap ~$126.8B.

What people say

The case for

Under Joyner, CVS has printed the cleanest incumbent turnaround in the sector: Q2 2026 revenue up 7.3% to $106.1B, FY2026 EPS guide raised $0.60 to $7.90-$8.10 (Drug Store News, August 2026), OCF guide raised to ≥$11.5B, stock up ~63% YoY (Stock Analysis, September 2026). Moody’s revised outlook to Positive citing the MA turnaround. Glenview publicly credited Joyner with strengthening culture and leadership when it trimmed 3.75M shares on a 25% gain (Fierce Healthcare). Aetna’s National PPO recovered to 4 stars for 2024 and MA margins are rebuilding. The FTC insulin settlement removes an overhang without gutting rebate economics. Vertical integration remains differentiated: no other pharmacy owns a top-three PBM and a top-four MA insurer.

The complaints

Six recurring themes. PBM share loss: Caremark’s 26% is down from a 2023 peak; loss of Blue Shield of California to Amazon + Cost Plus + Prime + Abarca in 2023 was the marquee defection (Healthcare Dive). Pharmacy safety: Ohio’s Board of Pharmacy imposed a $1.5M settlement in 2024 covering 27 cases at 22 CVS pharmacies (NBC News), citing understaffing, dispensing errors and dirty equipment; Reddit r/CVS catalogues technician-hour cuts and burnout; STAT News’ December 2025 pharmacist essay echoed the crisis. Aetna prior-auth: 11.6% MA denial rate (~1.5x industry) and 25.9% post-acute-care denial topped the Senate PSI October 2024 report; DOJ partial intervention in broker-kickback case May 2025 (Mintz). Retail: 1,170 stores gone by end 2025 (NBC Chicago). Regulatory: July 2026 FTC settlement forced binding Caremark practice changes. Governance: Lynch ousted after 44 months; Glenview took four board seats; fall 2024 strategic review fuelled sell-side breakup analysis.

Outlook: well positioned or at risk?

At-risk — the Joyner turnaround is real and the multiple has recovered, but the rubric warnings are lit. Three segments are structurally pressured. Retail dispensing is losing footprint on purpose (1,170 gone by end 2025) into a market where Amazon Pharmacy doubles annually, Cost Plus reprices generics at cost + 15% + $3, and Walmart/Costco/Kroger absorb front-of-store. Caremark has lost share two straight years, faces binding FTC practice changes from July 2026, and is attacked from below by pass-through PBMs employers now know to ask for by name. Aetna printed a $1B star-ratings hit in 2024, an MLR blowout that helped end Lynch’s tenure, an 11.6% MA prior-auth denial rate, and a DOJ broker-kickback case (partial intervention May 2025). Only Signify + Oak Street is unambiguously accretive, and Oak Street still requires MA plans to bear capitation risk.

The bull case is that vertical integration compounds — Caremark steers scripts, Aetna steers members, Signify/Oak Street close the loop on value-based care, retail does same-day specialty fulfilment. Defensible on the current print. But every leg is being separately unbundled: Amazon and Cost Plus attack retail; Navitus/Capital Rx/Prime attack the PBM with Congressional wind; Humana and UnitedHealth attack Aetna; Sycamore-owned Walgreens is a wild card. The base case shifts from “compounding integrated franchise” to “three separately contested businesses whose sum-of-the-parts depends on which leg breaks first.”

How to attack it

Wedge one: an AI-native, pass-through, fee-only PBM sold to self-insured employers on transparency. Caremark’s spread pricing, rebate retention and network-contracting are all under a binding FTC settlement as of July 2026, and Express Scripts already took Caremark share in each of the last two years (Drug Channels). A challenger stack — Capital Rx and Navitus exist as proof — that quotes on NADAC, rebates 100% to the plan, publishes contract terms, and layers agentic prior-auth automation on top walks into any RFP with a slide deck that reads better than Caremark on every axis except rebate float. Sell into the ~65M self-insured employer lives that increasingly hire Mercer, Segal and Aon to run RFPs. Wedge two: cash-pay generics + owned manufacturing + kiosk fulfilment. Cost Plus does 15% + $3 but is not yet profitable; a well-capitalised entrant bundling owned generics manufacturing (Civica Rx model), kiosk fulfilment at primary-care sites (Amazon’s October 2025 LA One Medical model) and a national mail-order backbone can price at Cost Plus levels with better unit economics and win the ~30% of Rx volume that is cash-pay or high-deductible.

Weaknesses to exploit: ~9,000-store real-estate base with $10B+ expense (10-K) a digital-first entrant does not carry; Caremark’s spread model, politically radioactive post-FTC; Aetna’s 11.6% prior-auth denial rate that every Congressional office has data on; the DOJ broker-kickback case (partial intervention May 2025); a $75B+ debt stack constraining counter-M&A; and the cultural PTSD from Lynch’s removal and Glenview activism slowing internal risk-taking. A funded team can pick one wedge and take a real bite out of one segment before the other two compensate.

Adjacent-segment play

The most defensible CVS asset that generalises to an adjacent buyer is the Signify + Oak Street VBC stack. Oak Street’s capitated model is transferable — Amazon paid $3.9B for One Medical, Humana built CenterWell, Walgreens’ VillageMD was the contingent-value asset in the Sycamore deal. Repackaged for a Medicaid-first buyer (Molina, Centene, Elevance) it becomes a state-plan risk-adjustment and SDOH platform CVS does not sell into. Repackaged for third-party ACO REACH and commercial VBC buyers, it becomes an OEM primary-care stack (the AWS-for-VBC positioning Aledade is chasing). Repackaged internationally, primary-care-in-a-box slots into UK/Canadian/Australian capitated systems. A separate adjacent play sits on Caremark specialty: specialty is 55%+ of drug spend and rising, and a specialty-only, fee-only PBM (Shields, Trellis Rx model) sold to health systems is defensible even if the general PBM race is lost. Where adjacent play does not work: front-of-store retail — Amazon, Walmart and Costco own it.

Sources and further reading

• CVS Health Q2 2026 Earnings Presentation (August 5, 2026)
• CVS Health FY2025 Annual Report (Form 10-K)
• The Top Pharmacy Benefit Managers of 2025 — Drug Channels, March 2026
• FTC Secures Major Settlement with Caremark — Federal Trade Commission, July 2026
• CVS strikes deal with activist Glenview Capital for four board seats — CNBC, November 18, 2024
• Blue Shield of California drops CVS Caremark — Healthcare Dive, August 2023
• CVS to pay Ohio $1.5 million over understaffing and safety issues — NBC News, 2024
• Senate report scrutinizes Medicare Advantage prior authorization denials — AHA News, October 17, 2024
• CVS closing 270 pharmacies in 2025 — NBC Chicago, 2025
• Walgreens Boots Alliance taken private in $10bn deal — Financier Worldwide, 2025
• CVS closes $10.6B acquisition of Oak Street Health — Fierce Healthcare, May 2023